Ascendis Health Limited (ASC.JO)
- Previous Close
84.00 - Open
87.00 - Bid 85.00 x --
- Ask 87.00 x --
- Day's Range
85.00 - 87.00 - 52 Week Range
63.00 - 104.00 - Volume
9,080 - Avg. Volume
374,094 - Market Cap (intraday)
532.139M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.47 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 10, 2017
- 1y Target Est
--
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa. It operates through Consumer Health, and Medical Devices segments. The company offers natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Preg, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Solal, and Vitaforce brand names. It also provides medical devices, and diagnostic laboratory equipment and consumables under the Reuterina, Pharmachem, Sinucon, Phlexy, Clonam, Surgical Innovations, RCA, and The Scientific Group brands. It also exports its products. The company serves pharmacies, private hospitals, and doctors, as well as government. Ascendis Health Limited was incorporated in 2008 and is based in Sandton, South Africa.
www.ascendishealth.comRecent News: ASC.JO
View MorePerformance Overview: ASC.JO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is All Share Index (^J203.JO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASC.JO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASC.JO
View MoreValuation Measures
Market Cap
532.14M
Enterprise Value
478.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.34
Price/Book (mrq)
0.95
Enterprise Value/Revenue
0.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
2.46%
Return on Assets (ttm)
-0.11%
Return on Equity (ttm)
2.78%
Revenue (ttm)
734.49M
Net Income Avi to Common (ttm)
18.08M
Diluted EPS (ttm)
-0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
4.18M
Total Debt/Equity (mrq)
17.19%
Levered Free Cash Flow (ttm)
278.71M